AU625856B2
(en)
*
|
1987-07-15 |
1992-07-16 |
United States of America, as represented by the Secretary, U.S. Department of Commerce, The |
Second generation monoclonal antibodies having binding specificity to tag-72 and human carcinomas and methods for employing the same
|
GB8720833D0
(en)
*
|
1987-09-04 |
1987-10-14 |
Celltech Ltd |
Recombinant dna product
|
JP3095168B2
(ja)
*
|
1988-02-05 |
2000-10-03 |
エル. モリソン,シェリー |
ドメイン‐変性不変部を有する抗体
|
KR0161525B1
(ko)
*
|
1988-10-19 |
1998-12-01 |
리챠드 지. 워터맨 |
암치료를 위한 신규의 고친화성 변형된 항체군
|
US5162218A
(en)
*
|
1988-11-18 |
1992-11-10 |
The Regents Of The University Of California |
Conjugated polypeptides and methods for their preparation
|
US5215889A
(en)
*
|
1988-11-18 |
1993-06-01 |
The Regents Of The University Of California |
Catalytic and reactive polypeptides and methods for their preparation and use
|
US5530101A
(en)
*
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
IL162181A
(en)
*
|
1988-12-28 |
2006-04-10 |
Pdl Biopharma Inc |
A method of producing humanized immunoglubulin, and polynucleotides encoding the same
|
GB8903021D0
(en)
*
|
1989-02-10 |
1989-03-30 |
Celltech Ltd |
Chemical compounds
|
US5714149A
(en)
*
|
1989-02-10 |
1998-02-03 |
Celltech Therapeutics Limited |
Crosslinked antibodies and processes for their preparation
|
GB8903022D0
(en)
*
|
1989-02-10 |
1989-03-30 |
Celltech Ltd |
Chemical compounds
|
US5354554A
(en)
*
|
1989-02-10 |
1994-10-11 |
Celltech Limited |
Crosslinked antibodies and processes for their preparation
|
GB8905669D0
(en)
*
|
1989-03-13 |
1989-04-26 |
Celltech Ltd |
Modified antibodies
|
CA2018248A1
(en)
*
|
1989-06-07 |
1990-12-07 |
Clyde W. Shearman |
Monoclonal antibodies against the human alpha/beta t-cell receptor, their production and use
|
GB8916400D0
(en)
*
|
1989-07-18 |
1989-09-06 |
Dynal As |
Modified igg3
|
US5859205A
(en)
*
|
1989-12-21 |
1999-01-12 |
Celltech Limited |
Humanised antibodies
|
EP0438310A1
(de)
*
|
1990-01-19 |
1991-07-24 |
Merck & Co. Inc. |
Verfahren zur Herstellung von rekombinanten Immunoglobulinen
|
US5185433A
(en)
*
|
1990-04-09 |
1993-02-09 |
Centocor, Inc. |
Cross-linking protein compositions having two or more identical binding sites
|
US5976531A
(en)
*
|
1990-04-19 |
1999-11-02 |
The Dow Chemical Company |
Composite antibodies of human subgroup IV light chain capable of binding to tag-72
|
US6495137B1
(en)
|
1990-04-19 |
2002-12-17 |
The Dow Chemical Company |
Humanized anti-tag-72 monoclonal antibodies using human subgroup 4 kappa light chains
|
GB9009548D0
(en)
*
|
1990-04-27 |
1990-06-20 |
Celltech Ltd |
Chimeric antibody and method
|
GB9009549D0
(en)
*
|
1990-04-27 |
1990-06-20 |
Celltech Ltd |
Recombinant antibody and method
|
GB2276169A
(en)
*
|
1990-07-05 |
1994-09-21 |
Celltech Ltd |
Antibodies specific for carcinoembryonic antigen
|
GB9014932D0
(en)
*
|
1990-07-05 |
1990-08-22 |
Celltech Ltd |
Recombinant dna product and method
|
GB9022543D0
(en)
*
|
1990-10-17 |
1990-11-28 |
Wellcome Found |
Antibody production
|
US5958413A
(en)
*
|
1990-11-01 |
1999-09-28 |
Celltech Limited |
Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
|
WO1994004679A1
(en)
*
|
1991-06-14 |
1994-03-03 |
Genentech, Inc. |
Method for making humanized antibodies
|
US6800738B1
(en)
|
1991-06-14 |
2004-10-05 |
Genentech, Inc. |
Method for making humanized antibodies
|
EP1400536A1
(de)
|
1991-06-14 |
2004-03-24 |
Genentech Inc. |
Verfahren zur Herstellung humanisierter Antikörper
|
AU654563B2
(en)
*
|
1991-07-24 |
1994-11-10 |
Imperial Chemical Industries Plc |
Proteins
|
EP0861893A3
(de)
*
|
1991-09-19 |
1999-11-10 |
Genentech, Inc. |
Hohe expression von immunglobulinen
|
WO1993012231A1
(en)
*
|
1991-12-13 |
1993-06-24 |
Dow Chemical (Australia) Limited |
Composite antibodies of human subgroup iv light chain capable of binding to tag-72
|
US5869619A
(en)
*
|
1991-12-13 |
1999-02-09 |
Xoma Corporation |
Modified antibody variable domains
|
US5766886A
(en)
*
|
1991-12-13 |
1998-06-16 |
Xoma Corporation |
Modified antibody variable domains
|
US5824307A
(en)
|
1991-12-23 |
1998-10-20 |
Medimmune, Inc. |
Human-murine chimeric antibodies against respiratory syncytial virus
|
JPH07505767A
(ja)
|
1992-02-06 |
1995-06-29 |
シェリング・コーポレーション |
ヒトインターロイキン−5に対するヒト化モノクローナル抗体の設計,クローン化および発現
|
US6056957A
(en)
*
|
1994-08-04 |
2000-05-02 |
Schering Corporation |
Humanized monoclonal antibodies against human interleukin-5
|
GB9422383D0
(en)
*
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
US5811524A
(en)
*
|
1995-06-07 |
1998-09-22 |
Idec Pharmaceuticals Corporation |
Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
|
US7569674B2
(en)
*
|
1998-05-04 |
2009-08-04 |
Innexus Biotechnology International Limited |
Autophilic antibodies
|
US20040185039A1
(en)
*
|
2002-08-30 |
2004-09-23 |
Heinz Kohler |
Therapeutic applications of noncovalent dimerizing antibodies
|
US20050033033A1
(en)
*
|
1998-05-04 |
2005-02-10 |
Heinz Kohler |
Trans-membrane-antibody induced inhibition of apoptosis
|
US6365124B1
(en)
*
|
1998-02-06 |
2002-04-02 |
Biocrystal, Ltd. |
Compositions for detecting and surgically removing lymphoid tissue involved in tumor progression
|
US20090208418A1
(en)
*
|
2005-04-29 |
2009-08-20 |
Innexus Biotechnology Internaltional Ltd. |
Superantibody synthesis and use in detection, prevention and treatment of disease
|
GB9812545D0
(en)
|
1998-06-10 |
1998-08-05 |
Celltech Therapeutics Ltd |
Biological products
|
US6818749B1
(en)
|
1998-10-31 |
2004-11-16 |
The United States Of America As Represented By The Department Of Health And Human Services |
Variants of humanized anti carcinoma monoclonal antibody cc49
|
ES2349348T3
(es)
*
|
2000-01-27 |
2010-12-30 |
Medimmune, Llc |
Anticuerpos neutralizantes de rsv de ultra alta afinidad.
|
US7153701B1
(en)
*
|
2000-02-17 |
2006-12-26 |
Hamamatsu Photonics K.K. |
Method for quantitatively detecting antigen
|
CA2401652A1
(en)
*
|
2000-03-01 |
2001-09-07 |
Medimmune, Inc. |
High potency recombinant antibodies and method for producing them
|
WO2001081401A1
(fr)
|
2000-04-21 |
2001-11-01 |
Fuso Pharmaceutical Industries, Ltd. |
Nouvelles collectines
|
US6855493B2
(en)
|
2000-11-28 |
2005-02-15 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US7179900B2
(en)
*
|
2000-11-28 |
2007-02-20 |
Medimmune, Inc. |
Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
|
US7396917B2
(en)
*
|
2000-12-05 |
2008-07-08 |
Alexion Pharmaceuticals, Inc. |
Rationally designed antibodies
|
US20040253242A1
(en)
*
|
2000-12-05 |
2004-12-16 |
Bowdish Katherine S. |
Rationally designed antibodies
|
ATE414720T1
(de)
*
|
2000-12-05 |
2008-12-15 |
Alexion Pharma Inc |
Rationell entworfene antikörper
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US20030133939A1
(en)
|
2001-01-17 |
2003-07-17 |
Genecraft, Inc. |
Binding domain-immunoglobulin fusion proteins
|
WO2002096948A2
(en)
|
2001-01-29 |
2002-12-05 |
Idec Pharmaceuticals Corporation |
Engineered tetravalent antibodies and methods of use
|
WO2002062850A2
(en)
*
|
2001-02-02 |
2002-08-15 |
Millennium Pharmaceuticals, Inc. |
Hybrid antibodies and uses thereof
|
AU2002248571B2
(en)
*
|
2001-03-07 |
2007-01-18 |
Merck Patent Gmbh |
Expression technology for proteins containing a hybrid isotype antibody moiety
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
AU2003248744C1
(en)
|
2002-06-28 |
2009-12-24 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Humanized anti-TAG-72 CC49 for diagnosis and therapy of human tumors
|
MXPA05004677A
(es)
|
2002-10-31 |
2005-11-17 |
Genentech Inc |
Metodos y composiciones para aumentar la produccion de anticuerpos.
|
GB0309126D0
(en)
|
2003-04-17 |
2003-05-28 |
Neutec Pharma Plc |
Clostridium difficile focussed antibodies
|
KR101412271B1
(ko)
|
2003-05-09 |
2014-06-25 |
듀크 유니버시티 |
Cd20-특이적 항체 및 이를 이용한 방법
|
EP1641826A2
(de)
*
|
2003-06-27 |
2006-04-05 |
Biogen Idec MA Inc. |
Verwendung der hydrophoben-interaktions-chromatographie oder hinge-regionen modifikationen zur herstellung homogener antikörperlösung
|
AU2004255216B2
(en)
|
2003-07-01 |
2010-08-19 |
Immunomedics, Inc. |
Multivalent carriers of bi-specific antibodies
|
GB0315457D0
(en)
*
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
GB0315450D0
(en)
*
|
2003-07-01 |
2003-08-06 |
Celltech R&D Ltd |
Biological products
|
US7989594B2
(en)
|
2003-07-01 |
2011-08-02 |
Celltech R & D Limited |
Modified antibody fab fragments
|
JP4818917B2
(ja)
*
|
2003-08-08 |
2011-11-16 |
イミューノメディクス、インコーポレイテッド |
腫瘍および罹患細胞のアポトーシスを誘発するための二重特異性抗体
|
US7589181B2
(en)
|
2003-08-29 |
2009-09-15 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
|
GB0325836D0
(en)
*
|
2003-11-05 |
2003-12-10 |
Celltech R&D Ltd |
Biological products
|
AU2004292393C1
(en)
|
2003-11-21 |
2011-08-04 |
Ucb Pharma S.A. |
Method for the treatment of multiple sclerosis by inhibiting IL-17 activity
|
GB0329825D0
(en)
*
|
2003-12-23 |
2004-01-28 |
Celltech R&D Ltd |
Biological products
|
WO2005103086A1
(en)
|
2004-04-23 |
2005-11-03 |
Bundesrepublik Deutschland letztvertreten durch das Robert-Koch-Institut vertreten durch seinen Präsidenten |
Method for the treatment of t cell mediated conditions by depletion of icos-positive cells in vivo
|
US20100111856A1
(en)
*
|
2004-09-23 |
2010-05-06 |
Herman Gill |
Zirconium-radiolabeled, cysteine engineered antibody conjugates
|
CA2580141C
(en)
|
2004-09-23 |
2013-12-10 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
CA2585891A1
(en)
*
|
2004-10-29 |
2006-05-11 |
Medimmune, Inc. |
Methods of preventing and treating rsv infections and related conditions
|
WO2006074399A2
(en)
*
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
BRPI0607486B8
(pt)
|
2005-03-03 |
2021-05-25 |
Immunomedics Inc |
anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos.
|
US20100104564A1
(en)
*
|
2005-03-29 |
2010-04-29 |
Genevieve Hansen |
Altered Antibody Fc Regions and Uses Thereof
|
USRE47223E1
(en)
|
2005-06-20 |
2019-02-05 |
Genentech, Inc. |
Compositions and methods for the diagnosis and treatment of tumor
|
GB0514779D0
(en)
*
|
2005-07-19 |
2005-08-24 |
Celltech R&D Ltd |
Biological products
|
UA97469C2
(uk)
|
2005-07-25 |
2012-02-27 |
Емерджент Продакт Дівелопмент Сіетл, Елелсі |
Гуманізована специфічна до cd37 зв'язувальна молекула імуноглобуліну
|
JP2009507980A
(ja)
*
|
2005-09-14 |
2009-02-26 |
ユセベ ファルマ ソシエテ アノニム |
櫛形ポリマー
|
PT1960430E
(pt)
|
2005-12-09 |
2015-01-05 |
Ucb Pharma Sa |
Moléculas de anticorpo com especificidade para il-6 humana
|
NZ569988A
(en)
|
2006-02-01 |
2011-09-30 |
Cephalon Australia Pty Ltd |
Domain antibody construct which binds to human TNF-alpha and contains a modified hinge region sequence and a truncated CH1 domain
|
NZ573646A
(en)
|
2006-06-12 |
2012-04-27 |
Wyeth Llc |
Single-chain multivalent binding proteins with effector function
|
GB0614780D0
(en)
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
GB0619291D0
(en)
|
2006-09-29 |
2006-11-08 |
Ucb Sa |
Altered antibodies
|
GB0620729D0
(en)
|
2006-10-18 |
2006-11-29 |
Ucb Sa |
Biological products
|
ES2523915T5
(es)
|
2006-12-01 |
2022-05-26 |
Seagen Inc |
Agentes de unión a la diana variantes y usos de los mismos
|
CN103214577B
(zh)
|
2007-03-22 |
2015-09-02 |
生物基因Ma公司 |
特异性结合cd154的包括抗体、抗体衍生物和抗体片段在内的结合蛋白及其用途
|
AU2008251608B2
(en)
|
2007-05-08 |
2014-03-27 |
Genentech, Inc. |
Cysteine engineered anti-MUC16 antibodies and antibody drug conjugates
|
EP1997830A1
(de)
|
2007-06-01 |
2008-12-03 |
AIMM Therapeutics B.V. |
RSV-spezifische Bindemoleküle und Mittel zu ihrer Herstellung
|
JP2010528664A
(ja)
*
|
2007-06-08 |
2010-08-26 |
ダウ グローバル テクノロジーズ インコーポレイティド |
Ch1ドメインの切断による可溶性抗体断片の発現
|
US8865875B2
(en)
|
2007-08-22 |
2014-10-21 |
Medarex, L.L.C. |
Site-specific attachment of drugs or other agents to engineered antibodies with C-terminal extensions
|
GB0717337D0
(en)
|
2007-09-06 |
2007-10-17 |
Ucb Pharma Sa |
Method of treatment
|
NZ584514A
(en)
|
2007-10-19 |
2012-07-27 |
Genentech Inc |
Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates
|
BRPI0819063A2
(pt)
|
2007-11-27 |
2020-08-18 |
The University Of British Columbia |
método para tratamento de artrite, anticorpo, hibridoma, antagonista de 14-3-3, usos de um antagonista de 14-3-3, composições farmacêuticas, método para redução da expressão de mmp no sinóvio de um paciente e usos de uma composição farmacêutica
|
EP2220117A2
(de)
|
2007-11-30 |
2010-08-25 |
Kalobios Pharmaceuticals, Inc. |
Antikörper gegen das pcrv-antigen von pseudomonas aeruginosa
|
ES2613963T3
(es)
*
|
2008-01-18 |
2017-05-29 |
Medimmune, Llc |
Anticuerpos manipulados con cisteína para conjugación específica de sitio
|
US20110044894A1
(en)
|
2008-03-26 |
2011-02-24 |
Cellerant Therapeutics, Inc. |
Immunoglobulin and/or Toll-Like Receptor Proteins Associated with Myelogenous Haematological Proliferative Disorders and Uses Thereof
|
NZ603059A
(en)
|
2008-04-11 |
2014-07-25 |
Emergent Product Dev Seattle |
Cd37 immunotherapeutic and combination with bifunctional chemotherapeutic thereof
|
GB0807413D0
(en)
|
2008-04-23 |
2008-05-28 |
Ucb Pharma Sa |
Biological products
|
JP5782385B2
(ja)
|
2009-02-17 |
2015-09-24 |
ユーシービー ファーマ ソシエテ アノニム |
ヒトox40に対する特異性を有する抗体分子
|
GB0904214D0
(en)
|
2009-03-11 |
2009-04-22 |
Ucb Pharma Sa |
Biological products
|
CA2758964A1
(en)
|
2009-04-16 |
2010-10-21 |
Abbott Biotherapeutics Corp. |
Anti-tnf-.alpha. antibodies and their uses
|
UA104626C2
(ru)
|
2009-06-17 |
2014-02-25 |
Эббви Биотерапеутикс Инк. |
Анти-vegf антитело и его применение
|
EP2475682B1
(de)
|
2009-09-10 |
2018-01-31 |
UCB Biopharma SPRL |
Polyvalente antikörper
|
GB0916630D0
(en)
|
2009-09-22 |
2009-11-04 |
Secr Defence |
Antibody
|
US8568726B2
(en)
|
2009-10-06 |
2013-10-29 |
Medimmune Limited |
RSV specific binding molecule
|
PT2488551T
(pt)
|
2009-10-16 |
2018-10-31 |
Inst Nat Sante Rech Med |
Anticorpos monoclonais contra a progastrina e suas utilizações
|
US9234037B2
(en)
|
2009-10-27 |
2016-01-12 |
Ucb Biopharma Sprl |
Method to generate antibodies to ion channels
|
GB0922435D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
Method
|
JP6095368B2
(ja)
|
2009-10-27 |
2017-03-15 |
ユセベ ファルマ ソシエテ アノニム |
機能改変するNav1.7抗体
|
GB0922434D0
(en)
|
2009-12-22 |
2010-02-03 |
Ucb Pharma Sa |
antibodies and fragments thereof
|
TW201122101A
(en)
|
2009-10-28 |
2011-07-01 |
Facet Biotech Corp |
Anti-EGFR antibodies and their uses
|
GB0920127D0
(en)
|
2009-11-17 |
2009-12-30 |
Ucb Pharma Sa |
Antibodies
|
GB0920324D0
(en)
|
2009-11-19 |
2010-01-06 |
Ucb Pharma Sa |
Antibodies
|
US8937159B2
(en)
|
2009-12-16 |
2015-01-20 |
Abbvie Biotherapeutics Inc. |
Anti-HER2 antibodies and their uses
|
GB201000467D0
(en)
|
2010-01-12 |
2010-02-24 |
Ucb Pharma Sa |
Antibodies
|
CN102892786B
(zh)
|
2010-03-11 |
2016-03-16 |
Ucb医药有限公司 |
Pd-1抗体
|
TW201134488A
(en)
*
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
CN106432474A
(zh)
|
2010-03-12 |
2017-02-22 |
艾伯维生物医疗股份有限公司 |
Ctla4蛋白和其用途
|
TR201903279T4
(tr)
|
2010-03-25 |
2019-03-21 |
Ucb Biopharma Sprl |
Disülfür stabilize edilmiş DVD-IG molekülleri.
|
GB201005064D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
CA2799540A1
(en)
|
2010-06-08 |
2011-12-15 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
GB201014033D0
(en)
|
2010-08-20 |
2010-10-06 |
Ucb Pharma Sa |
Biological products
|
RS56298B1
(sr)
|
2011-01-14 |
2017-12-29 |
Ucb Biopharma Sprl |
Antitelo koje vezuje il-17a i il-17f
|
EP2758432B1
(de)
|
2011-09-16 |
2019-03-06 |
UCB Biopharma SPRL |
Neutralisierende antikörper gegen die haupttoxine tcda und tcdb von clostridium difficile
|
UA112203C2
(uk)
|
2011-11-11 |
2016-08-10 |
Юсб Фарма С.А. |
Злитий білок біоспецифічного антитіла, який зв'язується з ox40 людини та сироватковим альбуміном людини
|
WO2013078455A2
(en)
|
2011-11-23 |
2013-05-30 |
The Board Of Regents Of The University Of Texas System |
Proteomic identification of antibodies
|
GB201203071D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
GB201203051D0
(en)
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
GB201208370D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
US20140154255A1
(en)
|
2012-11-30 |
2014-06-05 |
Abbvie Biotherapeutics Inc. |
Anti-vegf antibodies and their uses
|
GB201223276D0
(en)
|
2012-12-21 |
2013-02-06 |
Ucb Pharma Sa |
Antibodies and methods of producing same
|
DK2953976T3
(da)
|
2013-02-08 |
2021-06-21 |
Novartis Ag |
Specifikke modificeringssteder i antistoffer til fremstilling af immunkonjugater
|
JP6449229B2
(ja)
|
2013-03-15 |
2019-01-09 |
アッヴィ・バイオセラピューティクス・インコーポレイテッド |
Fc変異体
|
EP2970489A2
(de)
|
2013-03-15 |
2016-01-20 |
AbbVie Biotechnology Ltd |
Anti-cd25-antikörper und deren verwendungen
|
CN105377892A
(zh)
|
2013-03-15 |
2016-03-02 |
艾伯维生物技术有限公司 |
抗cd25抗体及其用途
|
GB201315487D0
(en)
|
2013-08-30 |
2013-10-16 |
Ucb Pharma Sa |
Antibodies
|
WO2015035044A2
(en)
|
2013-09-04 |
2015-03-12 |
Abbvie Biotherapeutics Inc. |
Fc VARIANTS WITH IMPROVED ANTIBODY-DEPENDENT CELL-MEDIATED CYTOTOXICITY
|
GB201320066D0
(en)
|
2013-11-13 |
2013-12-25 |
Ucb Pharma Sa |
Biological products
|
US9067998B1
(en)
|
2014-07-15 |
2015-06-30 |
Kymab Limited |
Targeting PD-1 variants for treatment of cancer
|
US8986694B1
(en)
|
2014-07-15 |
2015-03-24 |
Kymab Limited |
Targeting human nav1.7 variants for treatment of pain
|
US8992927B1
(en)
|
2014-07-15 |
2015-03-31 |
Kymab Limited |
Targeting human NAV1.7 variants for treatment of pain
|
US9045545B1
(en)
|
2014-07-15 |
2015-06-02 |
Kymab Limited |
Precision medicine by targeting PD-L1 variants for treatment of cancer
|
US9914769B2
(en)
|
2014-07-15 |
2018-03-13 |
Kymab Limited |
Precision medicine for cholesterol treatment
|
ES2916825T3
(es)
|
2014-01-20 |
2022-07-06 |
UCB Biopharma SRL |
Procedimiento para la reconstitución de una forma sólida de una composición farmacéutica
|
EP4190809A1
(de)
|
2014-02-11 |
2023-06-07 |
Seagen Inc. |
Selektive reduktion von proteinen
|
GB201403775D0
(en)
|
2014-03-04 |
2014-04-16 |
Kymab Ltd |
Antibodies, uses & methods
|
EP2944962A1
(de)
|
2014-05-14 |
2015-11-18 |
UCB Biopharma SPRL |
Verfahren zur Bestimmung von Antikörperspezifität
|
GB201411320D0
(en)
|
2014-06-25 |
2014-08-06 |
Ucb Biopharma Sprl |
Antibody construct
|
US9139648B1
(en)
|
2014-07-15 |
2015-09-22 |
Kymab Limited |
Precision medicine by targeting human NAV1.9 variants for treatment of pain
|
US10077318B2
(en)
|
2014-09-12 |
2018-09-18 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
US10035823B2
(en)
|
2014-09-29 |
2018-07-31 |
The Regents Of The University Of California |
Compositions for expanding regulatory T cells (TREG), and treating autoimmune and inflammatory diseases and conditions
|
PL3221346T3
(pl)
|
2014-11-21 |
2021-03-08 |
Bristol-Myers Squibb Company |
Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego
|
NZ731633A
(en)
|
2014-11-21 |
2022-01-28 |
Bristol Myers Squibb Co |
Antibodies against cd73 and uses thereof
|
EP3237432B1
(de)
|
2014-12-22 |
2023-09-06 |
UCB Biopharma SRL |
Proteinherstellung und reinigung
|
SG11201706659WA
(en)
|
2015-03-06 |
2017-09-28 |
Csl Behring Recombinant Facility Ag |
Modified von willebrand factor having improved half-life
|
GB201506869D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
GB201506870D0
(en)
|
2015-04-22 |
2015-06-03 |
Ucb Biopharma Sprl |
Method
|
TW201702271A
(zh)
|
2015-04-30 |
2017-01-16 |
哈佛大學校長及研究員協會 |
治療代謝病症之抗-ap2抗體及抗原結合劑
|
GB201508180D0
(en)
|
2015-05-13 |
2015-06-24 |
Ucb Biopharma Sprl |
Antibodies
|
EA039951B1
(ru)
|
2015-05-27 |
2022-03-31 |
Юсб Биофарма Спрл |
Ингибитор активности csf-1r, предназначенный для лечения или профилактики эпилепсии или болезни паркинсона, и фармацевтическая композиция на его основе
|
UA124616C2
(uk)
|
2015-07-06 |
2021-10-20 |
Юсб Біофарма Срл |
Зв'язуюче тау-білок антитіло
|
AU2016304764C1
(en)
|
2015-08-07 |
2023-06-01 |
Imaginab, Inc. |
Antigen binding constructs to target molecules
|
WO2017030156A1
(ja)
|
2015-08-19 |
2017-02-23 |
国立研究開発法人理化学研究所 |
非天然アミノ酸導入抗体
|
US11352426B2
(en)
|
2015-09-21 |
2022-06-07 |
Aptevo Research And Development Llc |
CD3 binding polypeptides
|
MX2018005031A
(es)
|
2015-10-27 |
2018-06-13 |
Ucb Biopharma Sprl |
Metodos de tratamiento con anticuerpos anti interleucina 17a/17f (il-17a/f).
|
US20180271998A1
(en)
|
2015-12-04 |
2018-09-27 |
Merrimack Pharmaceuticals, Inc. |
Disulfide-stabilized fabs
|
GB201522394D0
(en)
|
2015-12-18 |
2016-02-03 |
Ucb Biopharma Sprl |
Antibodies
|
EP3184544A1
(de)
|
2015-12-23 |
2017-06-28 |
Julius-Maximilians-Universität Würzburg |
Glycoprotein-v-inhibitoren zur verwendung als koagulansien
|
GB201602414D0
(en)
|
2016-02-10 |
2016-03-23 |
Nascient Ltd |
Biological materials and uses thereof
|
RS61412B1
(sr)
|
2016-03-17 |
2021-03-31 |
Tillotts Pharma Ag |
Anti-tnf alfa-antitela i njihovi funkcionalni fragmenti
|
US10759852B2
(en)
|
2016-03-17 |
2020-09-01 |
Numab Innovation Ag |
Anti-TNF-alpha-antibodies and functional fragments thereof
|
SG11201808041UA
(en)
|
2016-03-17 |
2018-10-30 |
Numab Innovation Ag |
ANTI-TNFa-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF
|
US10787508B2
(en)
|
2016-03-17 |
2020-09-29 |
Numab Innovation Ag |
Anti-TNFα-antibodies and functional fragments thereof
|
DK3219726T3
(da)
|
2016-03-17 |
2020-12-07 |
Tillotts Pharma Ag |
Anti-TNF-alfa-antistoffer og funktionelle fragmenter deraf
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
JP2020500834A
(ja)
|
2016-08-26 |
2020-01-16 |
エージェンシー フォー サイエンス,テクノロジー アンド リサーチ |
マクロファージ刺激タンパク質受容体(又はRON(Recepteur d′Origine Nantais))抗体及びその使用
|
GB201616596D0
(en)
|
2016-09-29 |
2016-11-16 |
Nascient Limited |
Epitope and antibodies
|
WO2018083248A1
(en)
|
2016-11-03 |
2018-05-11 |
Kymab Limited |
Antibodies, combinations comprising antibodies, biomarkers, uses & methods
|
GB201621635D0
(en)
|
2016-12-19 |
2017-02-01 |
Ucb Biopharma Sprl |
Crystal structure
|
WO2018147960A1
(en)
|
2017-02-08 |
2018-08-16 |
Imaginab, Inc. |
Extension sequences for diabodies
|
JP7337698B2
(ja)
|
2017-02-28 |
2023-09-04 |
シージェン インコーポレイテッド |
コンジュゲート化のためのシステイン突然変異抗体
|
US20200165347A1
(en)
|
2017-06-30 |
2020-05-28 |
Aslan Pharmaceuticals Pte Ltd |
Method of treatment using il-13r antibody
|
CA3084687C
(en)
|
2017-12-05 |
2024-01-02 |
Progastrine Et Cancers S.A R.L. |
Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
|
GB201802486D0
(en)
|
2018-02-15 |
2018-04-04 |
Ucb Biopharma Sprl |
Methods
|
AU2019228339A1
(en)
|
2018-02-27 |
2020-09-10 |
Ecs-Progastrin Sa |
Progastrin as a biomarker for immunotherapy
|
GB201811368D0
(en)
|
2018-07-11 |
2018-08-29 |
Ucb Biopharma Sprl |
Antibody
|
MX2021004351A
(es)
|
2018-10-16 |
2021-05-31 |
UCB Biopharma SRL |
Metodo para el tratamiento de miastenia grave.
|
AU2020247175A1
(en)
|
2019-03-26 |
2021-10-14 |
Aslan Pharmaceuticals Pte Ltd |
Treatment employing anti-IL-13R antibody or binding fragment thereof
|
AU2020342910A1
(en)
|
2019-09-04 |
2022-04-07 |
Pierre Fabre Medicament |
Anti-VSIG4 antibody or antigen binding fragment and uses thereof
|
GB201919058D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibodies
|
GB201919061D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Multi-specific antibody
|
GB201919062D0
(en)
|
2019-12-20 |
2020-02-05 |
Ucb Biopharma Sprl |
Antibody
|
GB202001447D0
(en)
|
2020-02-03 |
2020-03-18 |
Ucb Biopharma Sprl |
Antibodies
|
WO2022122652A1
(en)
|
2020-12-07 |
2022-06-16 |
UCB Biopharma SRL |
Antibodies against interleukin-22
|
MX2023006650A
(es)
|
2020-12-07 |
2023-06-21 |
UCB Biopharma SRL |
Anticuerpos multiespecificos y combinaciones de anticuerpos.
|
WO2022186772A1
(en)
|
2021-03-01 |
2022-09-09 |
Aslan Pharmaceuticals Pte Ltd |
TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
|
WO2022186773A1
(en)
|
2021-03-01 |
2022-09-09 |
Aslan Pharmaceuticals Pte Ltd |
TREATMENT OF ATOPIC DERMATITIS EMPLOYING ANTI-IL-13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF IN AN ALLERGIC POPULATION
|
KR20230156727A
(ko)
|
2021-03-03 |
2023-11-14 |
피에르 파브르 메디카먼트 |
항-vsig4 항체 또는 이의 항원 결합 단편 및 용도
|
TW202309088A
(zh)
|
2021-04-30 |
2023-03-01 |
法商皮爾法伯製藥公司 |
新的穩定抗vista抗體
|
IL308100A
(en)
|
2021-05-03 |
2023-12-01 |
UCB Biopharma SRL |
Antibodies
|
GB202111905D0
(en)
|
2021-08-19 |
2021-10-06 |
UCB Biopharma SRL |
Antibodies
|
WO2023048650A1
(en)
|
2021-09-27 |
2023-03-30 |
Aslan Pharmaceuticals Pte Ltd |
TREATMENT OF PRURITIS EMPLOYING ANTI-IL13Rα1 ANTIBODY OR BINDING FRAGMENT THEREOF
|
WO2023048651A1
(en)
|
2021-09-27 |
2023-03-30 |
Aslan Pharmaceuticals Pte Ltd |
Method for treatment of moderate to severe atoptic dematitis
|
TW202333784A
(zh)
|
2021-10-29 |
2023-09-01 |
新加坡商亞獅康私人有限公司 |
抗il13r抗體調配物
|
WO2023140780A1
(en)
|
2022-01-24 |
2023-07-27 |
Aslan Pharmaceuticals Pte Ltd. |
Method of treating inflammatory disease
|
TW202337905A
(zh)
|
2022-02-23 |
2023-10-01 |
新加坡商亞獅康私人有限公司 |
抗il13r抗體之糖基化形式
|
WO2024043837A1
(en)
|
2022-08-26 |
2024-02-29 |
Aslan Pharmaceuticals Pte Ltd |
High concentration anti-il13r antibody formulation
|
WO2024054157A1
(en)
|
2022-09-06 |
2024-03-14 |
Aslan Pharmaceuticals Pte Ltd |
Treatment for sleep loss or sleep disturbance in patients with dermatitis
|
WO2024121380A1
(en)
|
2022-12-08 |
2024-06-13 |
Pierre Fabre Medicament |
Vaccinal composition and adjuvant
|